Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease
Amamoo J, Wang Y, Liu H, et al. (2026). Advances in Therapy.
Summary
A retrospective study of US insurance claims comparing semaglutide injections with older oral diabetes drugs (sulfonylureas, DPP-4 inhibitors and thiazolidinediones) in adults with type 2 diabetes and chronic kidney disease. In people who could not take or had not responded well to SGLT2 inhibitors, semaglutide was associated at 12 months with larger falls in HbA1c, body weight and systolic blood pressure and a small rise in eGFR. In a second sample, semaglutide was associated with a lower risk of a combined outcome of dialysis, kidney transplant, severe loss of kidney function or death (adjusted hazard ratio 0.78). It is an observational study, so it shows associations rather than cause, and it was funded by Novo Nordisk, which makes semaglutide; five authors were Novo Nordisk employees.